PL2490532T3 - Nowe kompozycje do zapobiegania i/lub leczenia zaburzeń zwyrodnieniowych ośrodkowego układu nerwowego - Google Patents
Nowe kompozycje do zapobiegania i/lub leczenia zaburzeń zwyrodnieniowych ośrodkowego układu nerwowegoInfo
- Publication number
- PL2490532T3 PL2490532T3 PL10825396T PL10825396T PL2490532T3 PL 2490532 T3 PL2490532 T3 PL 2490532T3 PL 10825396 T PL10825396 T PL 10825396T PL 10825396 T PL10825396 T PL 10825396T PL 2490532 T3 PL2490532 T3 PL 2490532T3
- Authority
- PL
- Poland
- Prior art keywords
- preventing
- nervous system
- central nervous
- novel compositions
- degenerative disorders
- Prior art date
Links
- 210000003169 central nervous system Anatomy 0.000 title 1
- 230000003412 degenerative effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25280309P | 2009-10-19 | 2009-10-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2490532T3 true PL2490532T3 (pl) | 2017-05-31 |
Family
ID=43879775
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL10825396T PL2490532T3 (pl) | 2009-10-19 | 2010-10-05 | Nowe kompozycje do zapobiegania i/lub leczenia zaburzeń zwyrodnieniowych ośrodkowego układu nerwowego |
Country Status (26)
| Country | Link |
|---|---|
| US (4) | US8604206B2 (pl) |
| EP (2) | EP2490532B1 (pl) |
| JP (2) | JP5805649B2 (pl) |
| KR (3) | KR101813988B1 (pl) |
| CN (2) | CN105367485B (pl) |
| AR (1) | AR078606A1 (pl) |
| AU (3) | AU2010308396B2 (pl) |
| BR (1) | BR112012009121A2 (pl) |
| CA (1) | CA2778348C (pl) |
| CY (1) | CY1118966T1 (pl) |
| DK (1) | DK2490532T3 (pl) |
| ES (2) | ES2814178T3 (pl) |
| HR (1) | HRP20170236T1 (pl) |
| HU (1) | HUE033116T2 (pl) |
| IL (1) | IL219160B (pl) |
| LT (1) | LT2490532T (pl) |
| MX (2) | MX340807B (pl) |
| PL (1) | PL2490532T3 (pl) |
| PT (1) | PT2490532T (pl) |
| RS (1) | RS55679B1 (pl) |
| RU (2) | RU2015147509A (pl) |
| SG (1) | SG10201507159XA (pl) |
| SI (1) | SI2490532T1 (pl) |
| SM (2) | SMT201700105T1 (pl) |
| TW (1) | TWI642434B (pl) |
| WO (1) | WO2011049736A1 (pl) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2995306T (pt) | 2009-10-19 | 2019-03-29 | Amicus Therapeutics Inc | Novas composições para prevenção e/ou tratamento de disfunções de armazenamento lisossomal |
| DK2490532T3 (en) | 2009-10-19 | 2017-02-27 | Amicus Therapeutics Inc | Hitherto UNKNOWN COMPOSITIONS FOR PREVENTION AND / OR TREATMENT OF DEGENERATIVE DISORDERS IN THE CENTRAL Nervous System |
| EP2591823A1 (en) * | 2011-11-11 | 2013-05-15 | Biologische Heilmittel Heel GmbH | Composition for treating or preventing neurodegenerative disorders |
| CA2868459A1 (en) | 2012-03-27 | 2013-10-03 | Amicus Therapeutics, Inc. | Polymorphs of (3r,4r,5s)-5-(difluoromethyl)piperidine-3,4-diol fumarate and uses thereof |
| EP3087056A4 (en) * | 2013-12-23 | 2017-07-19 | Alectos Therapeutics Inc. | Glucocerebrosidase modulators and uses thereof |
| US10179128B2 (en) | 2015-08-31 | 2019-01-15 | Amicus Therapeutics, Inc. | Regimens for treating and preventing lysosomal disorders and degenerative disorders of the central nervous system |
| WO2018200618A1 (en) | 2017-04-25 | 2018-11-01 | Amicus Therapeutics, Inc. | Novel compositions for preventing and/or treating degenerative disorders of the central nervous system and/or lysosomal storage disorders |
| RU2676956C1 (ru) * | 2017-08-25 | 2019-01-11 | Общество с ограниченной ответственностью "Международный Биотехнологический Центр "Генериум" | Антитела для связывания имиглюцеразы и их применение в аффинной хроматографии |
| KR101991276B1 (ko) | 2018-01-19 | 2019-06-21 | 전남대학교산학협력단 | 신규 균주 페니실리움 아쿠아티쿰 및 이를 이용한 퇴행성 뇌질환 치료제 |
| US20220184185A1 (en) | 2018-07-25 | 2022-06-16 | Modernatx, Inc. | Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders |
| EP3962492A4 (en) * | 2019-04-29 | 2023-05-31 | Thomas Jefferson University | METHODS OF TREATMENT OF NEURODEGENERATIVE DISEASES |
| US20240262832A1 (en) * | 2021-04-30 | 2024-08-08 | Vanqua Bio, Inc. | Small molecule modulators of glucocerebrosidase activity and uses thereof |
| WO2022232360A1 (en) * | 2021-04-30 | 2022-11-03 | Vanqua Bio, Inc. | Small molecule modulators of glucocerebrosidase activity and uses thereof |
| WO2024163532A1 (en) * | 2023-01-31 | 2024-08-08 | Bioeutectics Corporation | Use of additives (adjuvants, anti freezing agents, antimicrobial and antioxidants) in natural deep eutectic solvents and mixtures |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4407957A (en) | 1981-03-13 | 1983-10-04 | Damon Corporation | Reversible microencapsulation of a core material |
| SG47470A1 (en) | 1991-04-25 | 1998-04-17 | Univ Brown Res Found | Implantable biocompatible immunoisolatory vehicle for delivery of a selected therapeutic products |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| US5569189A (en) | 1992-09-28 | 1996-10-29 | Equidyne Systems, Inc. | hypodermic jet injector |
| ATE220327T1 (de) | 1992-09-29 | 2002-07-15 | Inhale Therapeutic Syst | Pulmonale abgabe von aktiven fragmenten des parathormons |
| AU1890295A (en) * | 1994-03-09 | 1995-09-25 | Novo Nordisk A/S | Piperidines and pyrrolidines |
| US5863903A (en) * | 1994-03-09 | 1999-01-26 | Novo Nordisk A/S | Use of hydroxy alkyl piperidine and pyrrolidine compounds to treat diabetes |
| FR2718357B1 (fr) | 1994-04-06 | 1997-10-03 | Defarges Alain Moreau | Perfectionnements apportés à un dispositif d'injection par jet sans aiguille. |
| US5599302A (en) | 1995-01-09 | 1997-02-04 | Medi-Ject Corporation | Medical injection system and method, gas spring thereof and launching device using gas spring |
| US5780014A (en) | 1995-04-14 | 1998-07-14 | Inhale Therapeutic Systems | Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin |
| US5654007A (en) | 1995-06-07 | 1997-08-05 | Inhale Therapeutic Systems | Methods and system for processing dispersible fine powders |
| TW498067B (en) * | 1996-07-19 | 2002-08-11 | Hoffmann La Roche | 4-hydroxy-piperidine derivatives |
| US6274597B1 (en) * | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
| JP2006507359A (ja) * | 2002-10-28 | 2006-03-02 | ノボ・ノルデイスク・エー／エス | 心循環器疾患の治療のためのグリコーゲンホスホリラーゼ阻害剤の使用 |
| US20040082641A1 (en) * | 2002-10-28 | 2004-04-29 | Rytved Klaus Asger | Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases |
| US7446098B2 (en) | 2003-02-18 | 2008-11-04 | Mount Sinai School Of Medicine Of New York University | Combination therapy for treating protein deficiencies |
| US20070270350A1 (en) * | 2003-12-23 | 2007-11-22 | Musc Foundation For Research Development | Methods and Compositions for the Prevention and Treatment of Inflammatory Diseases or Conditions |
| ES2364586T3 (es) * | 2006-05-24 | 2011-09-07 | Amicus Therapeutics, Inc. | Sal tartrato de isofagomina y métodos de uso. |
| US7501439B2 (en) * | 2006-05-24 | 2009-03-10 | Amicus Therapeutics, Inc. | Tartrate salt of isofagomine and methods of use |
| ATE555788T1 (de) * | 2006-06-23 | 2012-05-15 | Amicus Therapeutics Inc | Verfahren zur behandlung neurologischer erkrankungen mittels verstärkung der beta - glucocerebrosidaseaktivität |
| WO2008134628A2 (en) | 2007-04-26 | 2008-11-06 | Amicus Therapeutics, Inc. | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
| WO2010015816A2 (en) | 2008-08-06 | 2010-02-11 | Summit Corporation Plc | Treatment of lysosomal storage disorders and other proteostatic diseases |
| BRPI1010517A2 (pt) | 2009-04-09 | 2017-01-31 | Amicus Therapeutics Inc | métodos para prevenção e/ou tratamento de doenças de armazenamento lisossomal |
| CA2758187C (en) * | 2009-04-09 | 2017-03-07 | Robert Boyd | Methods for preventing and/or treating degenerative disorders of the central nervous system |
| PT2995306T (pt) | 2009-10-19 | 2019-03-29 | Amicus Therapeutics Inc | Novas composições para prevenção e/ou tratamento de disfunções de armazenamento lisossomal |
| DK2490532T3 (en) * | 2009-10-19 | 2017-02-27 | Amicus Therapeutics Inc | Hitherto UNKNOWN COMPOSITIONS FOR PREVENTION AND / OR TREATMENT OF DEGENERATIVE DISORDERS IN THE CENTRAL Nervous System |
| JP6061677B2 (ja) * | 2009-10-19 | 2017-01-18 | アミカス セラピューティックス インコーポレイテッド | 薬理シャペロンを用いてガングリオシドの活性を増大させて、アルツハイマー病を治療するための方法 |
| KR102023720B1 (ko) | 2012-09-03 | 2019-09-20 | 엘지이노텍 주식회사 | 보이스 코일 모터 |
-
2010
- 2010-10-05 DK DK10825396.4T patent/DK2490532T3/en active
- 2010-10-05 RU RU2015147509A patent/RU2015147509A/ru unknown
- 2010-10-05 JP JP2012535221A patent/JP5805649B2/ja active Active
- 2010-10-05 MX MX2012004548A patent/MX340807B/es active IP Right Grant
- 2010-10-05 KR KR1020177022493A patent/KR101813988B1/ko not_active Expired - Fee Related
- 2010-10-05 WO PCT/US2010/051447 patent/WO2011049736A1/en not_active Ceased
- 2010-10-05 RS RS20170153A patent/RS55679B1/sr unknown
- 2010-10-05 SI SI201031401A patent/SI2490532T1/sl unknown
- 2010-10-05 CN CN201510783936.0A patent/CN105367485B/zh not_active Expired - Fee Related
- 2010-10-05 CA CA2778348A patent/CA2778348C/en active Active
- 2010-10-05 PT PT108253964T patent/PT2490532T/pt unknown
- 2010-10-05 HU HUE10825396A patent/HUE033116T2/en unknown
- 2010-10-05 BR BR112012009121A patent/BR112012009121A2/pt not_active Application Discontinuation
- 2010-10-05 ES ES16191218T patent/ES2814178T3/es active Active
- 2010-10-05 EP EP10825396.4A patent/EP2490532B1/en active Active
- 2010-10-05 RU RU2012120759/04A patent/RU2581058C2/ru active
- 2010-10-05 PL PL10825396T patent/PL2490532T3/pl unknown
- 2010-10-05 HR HRP20170236TT patent/HRP20170236T1/hr unknown
- 2010-10-05 KR KR1020127012936A patent/KR101769396B1/ko not_active Expired - Fee Related
- 2010-10-05 ES ES10825396.4T patent/ES2617192T3/es active Active
- 2010-10-05 SG SG10201507159XA patent/SG10201507159XA/en unknown
- 2010-10-05 EP EP16191218.3A patent/EP3143875B1/en active Active
- 2010-10-05 LT LTEP10825396.4T patent/LT2490532T/lt unknown
- 2010-10-05 SM SM20170105T patent/SMT201700105T1/it unknown
- 2010-10-05 US US12/898,112 patent/US8604206B2/en active Active
- 2010-10-05 AU AU2010308396A patent/AU2010308396B2/en not_active Ceased
- 2010-10-05 KR KR1020177037220A patent/KR101880411B1/ko not_active Expired - Fee Related
- 2010-10-05 CN CN2010800566279A patent/CN102655747A/zh active Pending
- 2010-10-05 MX MX2016000153A patent/MX368459B/es unknown
- 2010-10-12 AR ARP100103715A patent/AR078606A1/es unknown
- 2010-10-12 TW TW099134782A patent/TWI642434B/zh not_active IP Right Cessation
-
2012
- 2012-04-15 IL IL219160A patent/IL219160B/en not_active IP Right Cessation
-
2013
- 2013-11-19 US US14/084,131 patent/US9409862B2/en active Active
-
2015
- 2015-03-30 JP JP2015069784A patent/JP6258245B2/ja active Active
-
2016
- 2016-06-08 AU AU2016203817A patent/AU2016203817B2/en not_active Ceased
- 2016-07-22 US US15/217,217 patent/US20160326114A1/en not_active Abandoned
-
2017
- 2017-02-16 SM SM201700105T patent/SMT201700105B/it unknown
- 2017-02-22 CY CY20171100240T patent/CY1118966T1/el unknown
- 2017-12-07 AU AU2017272296A patent/AU2017272296B2/en not_active Ceased
-
2018
- 2018-06-01 US US15/995,813 patent/US10421724B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL219160A0 (en) | Novel compositions for preventing and/or treating degenerative disorders of the central nervous system | |
| IL215584A0 (en) | Methods for preventing and/or treating degenerative disorders of the central nervous system | |
| GB201001047D0 (en) | Methods and compositions for the treatment of neurological disorders | |
| EP2170309A4 (en) | METHOD AND COMPOSITIONS FOR THE TREATMENT OF DISEASES | |
| EP2552433A4 (en) | COMPOSITIONS AND METHODS OF TREATING SOMATOSENSORY DISEASES | |
| ZA201204658B (en) | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders | |
| EP2331088A4 (en) | COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC ILLNESSES | |
| IL209032A0 (en) | Compositions and methods for treating digestive disorders | |
| SI2430022T1 (sl) | 1,2,3-triazolo(4,3-a)piridin derivati in njihova uporaba za zdravljenje ali prepreäśevanje nevroloĺ kih in psihiatriäśnih nepravilnosti | |
| MY165728A (en) | Selective glycosidase inhibitors and uses thereof | |
| WO2011049960A9 (en) | Compositions and methods for the treatment of sinonasal disorders | |
| MY159856A (en) | Compounds, compositions and methods for protecting brain health in neurodegenerative disorders | |
| WO2011069063A3 (en) | Multicyclic compounds and methods of use thereof | |
| PT2300614E (pt) | Métodos e composições para tratamento de distúrbios mitocondriais | |
| SI2252300T1 (sl) | Uporaba 2,4-pirimidindiaminov za zdravljenje ateroskleroze | |
| GB2495885B (en) | Combination pharmaceutical composition and methods of treating genitourinary system disorders | |
| EP2370415A4 (en) | COMPOSITIONS AND METHODS FOR INHIBITING THE JAK PATH | |
| EP2475390A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF TYROSINE KINASE RECEPTOR MEDIATION DISEASES OR DISORDERS | |
| EP2612668A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF DEGENERATIVE NEUROLOGICAL CEREBRAL DISORDERS | |
| IL220364A0 (en) | Compounds for the treatment of neurologic disorders | |
| HU0900231D0 (en) | Compositions for the treatment of allergic disorders | |
| EP2219650A4 (en) | COMPOSITIONS AND METHODS FOR TREATING FIBROPROLIFERATIVE DISORDERS | |
| MX2011013073A (es) | Compuestos 1-(2-alquil-2,3-dihidro-benzofuran-4-il)-pirrolidin-3-i laminoacilo. | |
| EP2578206A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DISORDERS OF THE LOWER PART OF THE UROGENITAL SYSTEM | |
| EP2459507A4 (en) | USE OF ERYTHRITOL FOR THE PREVENTION OR TREATMENT OF HYPERTONIA |